Roche has reported highly positive Phase III results for its investigational drugs fenebrutinib in multiple sclerosis and Gazyva/Gazyvaro in systemic lupus erythematosus, showing significant clinical benefits over standard therapies and meeting all primary and key secondary endpoints.
This breadth of late-stage success highlights Roche’s capabilities in advancing novel treatments for large, high-unmet-need autoimmune diseases, reinforcing its position as a leader in neurology and immunology innovation.
We’ll explore how progress in multiple sclerosis and lupus therapies could reshape Roche’s earnings outlook and pipeline-driven growth story.
These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump’s tariffs. Discover why before your portfolio feels the trade war pinch.
Owning Roche Holding means believing in the company’s ability to consistently deliver high-value innovation across pharmaceuticals and diagnostics, while managing pressure from biosimilar competition and ongoing healthcare price reforms. The latest phase III success for fenebrutinib in multiple sclerosis and Gazyva in lupus provides strong near-term pipeline momentum, potentially offsetting upcoming patent risks, but does not yet materially alter the looming challenge of biosimilar erosion post-2026.
The recent ALLEGORY phase III trial results for Gazyva in systemic lupus erythematosus directly add to Roche’s growing autoimmune portfolio, providing additional evidence of successful pipeline execution supporting future earnings resilience as legacy products face headwinds.
But unlike the optimism brought by breakthrough trial data, risks tied to accelerated biosimilar competition after 2026 remain information investors need to be aware of, especially as…
Read the full narrative on Roche Holding (it’s free!)
Roche Holding’s outlook anticipates CHF67.3 billion in revenue and CHF16.8 billion in earnings by 2028. This is based on a 1.9% annual revenue growth rate and a CHF7.4 billion earnings increase from the current CHF9.4 billion.
Uncover how Roche Holding’s forecasts yield a CHF298.64 fair value, a 3% upside to its current price.
SWX:ROG Community Fair Values as at Nov 2025
Simply Wall St Community members submitted seven unique fair value estimates for Roche spanning CHF298.64 to CHF705.80 per share. While optimism surrounds Roche’s pipeline wins, the risk of sharp post-2026 biosimilar-driven sales declines illustrates why investor opinions on the future can differ widely, explore several community perspectives.
Explore 7 other fair value estimates on Roche Holding – why the stock might be worth just CHF298.64!
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com